**Name of Journal: *World Journal of Gastrointestinal Oncology***

**ESPS Manuscript NO: 21759**

**Manuscript Type: Review**

**Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7 and pronecrotic mixed lineage kinase domain - like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas**

Seldon CS *et al*. Prognostic biomarkers in pancreatic adenocarcinomas

**Crystal S Seldon, Lauren E Colbert, William A Hall, Sarah B Fisher, David S Yu, Jerome C Landry**

**Crystal S Seldon, David S Yu, Jerome C Landry**, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States

**Lauren E Colbert**, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States

**William A Hall**, Department of Radiation Oncology, the Medial College of Wisconsin, Milwaukee, WI 53226, United States

**Sarah B Fisher**, Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, United States

**Author contributions**: Seldon CS wrote the paper. Colbert LE, Hall WA, Fisher SB, Yu DS, and Landry JC equally contributed to this paper with data collection, design, review, editing, and approval of the final version.

**Supported by** The National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers ULl TR000454 previously awarded to Dr. Colbert and Dr. Fisher and TLlTR000456 to Dr. Colbert and Pancreatic Cancer Action Network (Pan-CAN)&solAmerican Association for Cancer Research (AACR) award 16982, Department of Defense (DOD)/ Peer Reviewed Cancer Research Program (PRCRP) award CA110535, and Georgia Cancer Coalition award 11072, all to Dr. Yu.

**Conflict-of-interest** **statement:** No potential conflicts of interest were disclosed.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Jerome C Landry, MD, MBA**, **Assistant Professor,** Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, NE, Suite C3008, Atlanta, GA 30322, United States. [jland01@emory.edu](mailto:jland01@emory.edu)

**Telephone**: +1-404-6166349

**Fax**: +1-404-6166380

**Received:** July 28, 2015

**Peer-review started:** July 29, 2015

**First decision:** November 3, 2015

**Revised:** December 5, 2015

**Accepted:** January 8, 2016

**Article in press:**

**Published online:**

**Abstract**

Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. These markers can be used clinically to optimize and personalize therapy for individual patients. In this review, we focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain- like protein. The aim of this article is to review present literature provided for these biomarkers and current studies in which their effectiveness as prognostic biomarkers are analyzed in order to determine their future use as biomarkers in clinical medicine. Based on the data presented, these biomarkers warrant further investigation, and should be validated in future studies.

**Key words:** Chromodomain-helicase-DNA binding protein 5; Chromodomain-helicase-DNA binding protein 7; Mixed lineage kinase domain-like protein; Pancreatic adenocarcinoma; Biomarker

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in studies and research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. We focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain- like protein. Based on the data presented, these biomarkers warrant further investigation.

Seldon CS, Colbert LE, Hall WA, Fisher SB, Yu DS, Landry JC. Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7 and pronecrotic mixed lineage kinase domain - like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. *World J Gastrointest Oncol* 2016; In press

**INTRODUCTION**

With an estimated 39, 590 deaths in 2014, pancreatic cancer is the fourth leading cause of death from cancer in the United States[1]. Pancreatic adenocarcinoma (PAC), the most common type of pancreatic cancer, has a very poor prognosis with a five year survival rate of 5%for patients with all stages of disease[2]. Patients with early- stage resected PAC have the best prognosis when followed by treatment with adjuvant therapy[3,4], with a median overall survival (OS) of approximately 3 years[5]. Potential predictive and prognostic biomarkers could play an important role in determining the most effective and productive treatment for individual patients. PAC is genetically heterogeneous and several well-known and some newly defined core signaling pathways likely play a role in development and behavior of PAC, including necroptosis, a form of cell death, and the DNA damage response pathway[6]. In this review, we will explore those pathways and putative biomarkers associated with them.

**BIOMARKERS AND PAC**

The FDA defines a biomarker as “any measureable diagnostic indicator that is used to assess the risk or presence of disease”[8]. In recent years, there has been a tremendous increase in research directed towards identifying biomarkers in specific cancers. There are many biomarkers being used in other cancers that aid in the diagnosis and establishment of personalized treatment for patients. Though the use of biomarkers in the treatment of cancer is expanding, the role of biomarkers in the treatment of patients with PAC trails behind. To date, CA 19-9, discovered in 1981, remains as the only FDA approved biomarker in diagnosing PAC. Other cancers are also associated with elevated CA 19-9 levels including the following: colorectal[9], esophageal[10], lung[11], ovarian[12], and breast[10], making CA 19-9 a nonspecific marker. Patients with pancreatitis, elevated bilirubin levels, and cirrhosis can also present with elevated CA 19-9 levels[13]. This makes it difficult to determine whether these levels are high due to tumor involvement or non- cancerous events. CA 19-9 is also viewed as a poor prognostic tool due to the fact that it is not expressed in 10% of Caucasians and 40% of Africans[14]. This is due to a deficiency in fucosyltransferase enzyme which is involved in the production of CA 19-9 and Lewis antigen[27]. Currently, CA 19-9 is most useful as a diagnostic tool when measured after resection for disease recurrence[15].

Prognostic biomarkers that hold promise are SMAD4 and glypican- 1 (GPC1). GPC1 is a cell surface proteoglycan located on cancer- cell- derived exosomes. Melo *et al*[16] were able to distinguish between healthy subjects and patients with a benign pancreatic disease from patients with early- and late-stage pancreatic cancer by measuring serum levels of GPC1+ circulating exosomes (crExos). Levels of GPC1+ crExos also were found to connect with tumor burden and the survival of pre- and post-surgical patients[16].

Mutations that inactivate SMAD Family Member 4 (SMAD4) occur most commonly in pancreatic cancers *vs* other cancer types[17]. SMAD4 is silenced in 53% of pancreatic cancer cases[18]. SMAD4 expression is lost through loss of heterozygosity and intragenetic mutations along with other alterations such as KRAS mutations[19]. KRAS mutations, located in 95% of pancreatic cancers[20], are usually followed by loss of SMAD4 in late development of PAC[21]. Loss of SMAD4 promotes the progression of preneoplastic lesions and is associated with worse prognosis in patients with PAC. Numerous studies support this claim[22-27]. Blackford *et al*[22] determined that patients whose cancers lacked SMAD4 expression had significantly worse survival outcomes than patients with normal SMAD4 expression. Tascilar *et al*[23] built on this observation by showing that the loss of expression of the SMAD4 protein by immunolabeling is associated with poor prognosis in patients with resected PAC, and patients with intact SMAD4 expression survived significantly longer than patients whose cancers lacked SMAD4 (median survival, 19.2 *vs* 14.7 mo; *P* = 0.03). Biankin *et al*[24] concluded that SMAD4 expression predicted increased survival and improved response to surgery. Reduced survival in colon cancer was associated with decreased SMAD4 expression in a study conducted by Isaksson-Mettavainio *et al*[25]. Reduced SMAD4 expression is also present in head- and – neck squamous cell carcinomas and esophageal squamous cell carcinoma[19]. SMAD4 expression is lost in 40%-50% of colon cancers[25] and 25% of prostate cancers[26]. In 45% of cholangiocarcinomas, loss of SMAD4 expression is present and associated with more aggressive tumor behavior[27].

***Identifying biomarkers***

Identification and validation of predictive biomarkers for responsiveness to adjuvant therapy is extremely important for patients with PAC. These markers can be used clinically to optimize and personalize therapy for individual patients. At this point, no biomarkers have been identified to reliably predict patient outcome, and more knowledge of potential biomarkers may aid in tailoring and directing patient therapy. Our group has previously identified several potential prognostic markers involved in either the necroptotic or DDR pathway including chromodomain-helicase-DNA binding protein 5 (CHD5), chromodomain-helicase-DNA binding protein 7 (CHD7), and mixed lineage kinase domain- like protein (MLKL) (Table 1).

***DDR serves as cancer barrier***

As defined by Curtin *et al*[28] the DDR is a series of pathways that “coordinates the repair of DNA and the activation of cell cycle checkpoints to arrest the cell to allow time for repair”. The DDR has evolved in order to maintain the genomic integrity of the cell. It constantly protects the cell from endogenous and environmental damage that could disrupt DNA by causing single stranded breaks (SSBs) or double stranded breaks (DSBs). The DDR acts as a cancer barrier by activating DNA repair mechanisms and apoptosisso that unstable cells will not replicate and result in DDR related diseases and precancerous lesions.

One pathway of the DDR is homologous recombination repair (HRR). Occurring during the S and G2 phases of the cell cycle[29], HRR is associated with familial forms of pancreatic cancer associated with the following genes: *BRCA1, BRCA2, PALB2, ATM, RAD51D,* and *RAD51C*[30]*.* HRR repairs DSBs. γH2Ax foci are markers for DSBs in precancerous lesions. These markers are produced during a phosphorylation reaction following chromatin engulfing the DSB[31,32].

Data has shown that the DDR may promote the survival of PAC that outgrows the selection pressure of DDR activation[33]. Many DDR genes are somatically mutated in PAC, including *ATM, BRCA2, CDKN2A, FANCI, HELB, and RAD9*[34]. Dysregulated expression of tumor suppressor genes that induce DDR activation can function as biomarkers for poor outcome.

***CHD5 functions as a tumor suppressor gene***

CHD5 is a member of a family of chromodomain enzymes that belong to the ATP- dependent chromatin remodeling protein superfamily. It has been suggested that CHD5 is the master regulator of a tumor- suppressive network[35]. CHD5 is regulated by DNA methylation of its promotor and histone modifications. The ability of CHD5 to bind unmodified histone 3 is essential for tumor suppression[36]. CHD5 is epigenetically silenced in neuroblastoma[37], colorectal cancer[38], breast cancer[39], cervical cancer[39], hepatocarcinoma[39], gastric cancer[40] and lung cancer[41]. Mutations in CHD5 have been found in head and neck squamous cell carcinoma[42], prostate cancer[43], ovarian cancer[44], ovarian clear cell carcinoma[45], cutaneous melanoma[46], hepatocellular carcinoma[47], neuroblastoma[48], breast and colorectal cancer[49]. In a study conducted by Bagchi *et al*[50] loss of CHD5 enhanced tumor proliferation whereas restoration of CHD5 inhibited proliferation. The function of CHD5 has mainly been studied in neural tissues where it was determined to control cell death and replication *via* the p19(Arf)/p53 pathway[50]. CHD5 is also a putative substrate of the ATM/ATR checkpoint kinases, suggesting that it may have a role in the DDR[51].

***Silencing of CHD5 activates the DDR***

Expression of CHD5 corresponds with a cell’s capability of locating and repairing DNA damage in cells. In a study conducted by Hall *et al*[33] preclinical data showed increased levels of γH2AX foci markers suggesting increased levels of DSBs in pancreatic cancer cells. This was correlated with low CHD5 expression in those cells. As a result, activation of the DDR presumes due to the presence of collapsed replication forks[33].

***Low CHD5 expression is associated with worse clinical outcomes***

In the same study by Hall *et al*[33] the relationship between CHD5 levels in pancreatic cells and DDR activation was evaluated in a clinical population. The overall survival (OS) of 80 patients with resected PAC was analyzed in conjunction with CHD5 expression. Low CHD5 expression was associated with decreased recurrence free survival (RFS) and decreased OS in patients with PAC (5.3 *vs* 15.4 mo, *P* = 0.03)[33]. The association between low CHD5 expression and poor survival has also been documented in other cancers, including gallbladder carcinoma[52], neuroblastoma[53], ovarian cancer[54], and breast cancer[55].

***CHD5 as a prognostic biomarker***

Available data seems to reflect that low CHD5 expression suggests a poor prognosis. If validated in an independent cohort, low CHD5 expression could be used to select patients with particularly aggressive disease for further adjuvant therapy. Due to its clinical relevance as both a tumor suppressor and a prognostic factor in numerous cancers, study of CHD5 function in the DDR warrants further review.

***CHD7 as a potential DDR substrate***

CHD7 is a member of a family of chromodomain enzymes that encode an ATP- dependent chromatin remodeler. Mutations in CHD7 causes CHARGE syndrome, a multiple anomaly disorder that presents with a variety of phenotypes, including ocular coloboma, heart defects, choanal atresia, retarded growth and development, genitourinary hypoplasia, and ear abnormalities[56]. Mutations in CHD7 also cause Kallman Syndrome, a genetic disorder marked by hypogonadotropic hypogonadism and anosmia[57], and associated with colorectal carcinomas[58]. CHD7 helps to regulate neural crest gene expression[59], regulates ribosomal RNA biogenesis[60], and interacts with SOX2 to regulate gene expression[61]. CHD7 is also a potential substrate of the ATM/ATR checkpoint kinases, suggesting a role in the DDR[51,62]. CHD7 is also dysregulated in 13% to 35% of cases of pancreatic adenocarcinoma, with aberrant expression, copy-number variation, and somatic mutations[63-65].

***Low CHD7 expression associated with better prognosis***

Colbert *et al*[66] suggested that CHD7 deficiency may play a role in gemcitabine sensitization in pancreatic adenocarcinoma cells and delayed pancreatic tumor xenograft growth in mice treated with gemcitabine. Additionally, they showed that CHD7 knockdown impaired ATR-dependent phosphorylation of CHK1 and increased gemcitabine-induced DNA damage in vitro, revealing a novel function for CHD7 as a DDR protein: the maintenance of genome integrity in response to gemcitabine[66]. Low CHD7 expression was also associated with improved RFS and OS in a retrospective analysis of patients with early-stage resected pancreatic adenocarcinoma treated with adjuvant gemcitabine[65].

***CHD7 as a prognostic biomarker***

The study conducted by Colbert *et al*[66] suggests that CHD7 expression could potentially be explored as a prognostic biomarker to personalize adjuvant therapy for these patients by determining which patients will receive greater benefit from gemcitabine therapy and allowing clinicians a way to better select patients for specific adjuvant therapy regimens in the future.

***The necroptotic pathway and MLKL***

Cell death is mediated through two processes, necrosis and apoptosis. Apoptosis is characterized by chromatin condensation, cell shrinkage, plasma membrane blebbing, and formation of apoptotic bodies[67]. Necrosis is characterized by oncosis, organelle swelling, and plasma membrane rupture[68]. Many cancer treatments, including chemotherapy and radiation, induce necrotic cell death[68-70]. Necrosis has been deemed a passive and unregulated process in contrast to apoptosis, however, emerging evidence has shown that necrosis can occur in a regulated and controlled manner[71]. TNF- induced necrotic death is called necroptosis[72]. Necroptosis is dependent on the activities of receptor- interacting protein kinase 1 (RIPK1) and 3 (RIPK3)[68].

Along with RIPK1 and RIPK3, MLKL forms the necrosis- inducing complex called a “necrosome”[73]. MLKL is considered a dead kinase due to its lack of phosphate-binding glycine-rich P loop and the absence of a key amino acid, aspartate, required for kinase activity. The necrosome induces cell death through the phosphorylation of MLKL by RIPK3 through the kinase- like domain[73]. The activity between MLKL and RIPK3 is amplified by TNF-α- mediated RIPK1 activation[73].

***Low MLKL associated with worse prognosis***

Colbert *et al*[74] explored MLKL expression as a potential prognostic biomarker in patients undergoing resection for early- stage PAC. Low expression of MLKL was associated with decreased OS regardless of whether adjuvant therapy was used [74]. The HR for death associated with low MLKL expression became stronger in the group of patients treated with adjuvant therapy than in all patients, and was strongest in those patients receiving gemcitabine chemotherapy[74]. In a study conducted by He *et al*[75] low expression of MLKL was significantly associated with decreased DFS and OS in patients with primary ovarian cancer. The finding low MLKL expression is associated with worse outcomes in patients with primary ovarian cancer and early- stage PAC may be a result of decreased necroptosis signaling. This suggests that necroptosis is an important determinant of cancer cell death and outcome of patients with these cancers[75]. Study of this gene warrants further analysis as patients with low MLKL expression may benefit from more aggressive chemotherapy regimens or participation in clinical trials due to the low probability that they will benefit from traditional adjuvant therapy. Although MLKL expression may be a useful prognostic marker, further studies should be performed in other patient populations and in larger studies for validation. Also, future studies should also examine the role of MLKL in predicting response to gemcitabine therapy.

**CONCLUSION**

In the biomarker studies conducted for CHD5, CHD7, and MLKL, each individual gene might serve as an independent prognostic biomarker for patients with early-stage resected PAC. The findings presented provide hypothesis generating momentum to study the expression of these genes in prospective cohorts undergoing adjuvant therapy for PAC. In future studies, using larger patient cohorts, it can be determined whether multiple gene expression provides a more accurate prognostic value than single gene expression alone. The potential exists for clinicians to use biomarkers such as CHD5, CHD7, and MLKL to select the most beneficial therapy regimens and tailor them for individual patients in the future.

**REFERENCES**

1 **Siegel R**, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014; **64**: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208]

2 **Yadav D**, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 2013; **144**: 1252-1261 [PMID: 23622135 DOI: 10.1053/j.gastro.2013.01.068]

3 **Heinemann V**, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. *Cancer Treat Rev* 2012; **38**: 843-853 [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004]

4 **Neoptolemos JP**, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA* 2010; **304**: 1073-1081 [PMID: 20823433 DOI: 10.1001/jama.2010.127510.1001]

5 **Kim EJ**, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. *Cancer* 2013; **119**: 2692-2700 [PMID: 23720019 DOI: 10.1002/cncr.28117]

6 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]

7 **Karhu R**, Mahlamäki E, Kallioniemi A. Pancreatic adenocarcinoma -- genetic portrait from chromosomes to microarrays. *Genes Chromosomes Cancer* 2006; **45**: 721-730 [PMID: 16688744 DOI: 10.1002/gcc.20337]

8 **Gutman S**, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. *Nat Rev Cancer* 2006; **6**: 565-571 [PMID: 16794639 DOI: 10.1038/nrc1911]

9 **Forones NM**, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer. *Hepatogastroenterology* 1999; **46**: 905-908 [PMID: 10370636]

10 **Loy TS**, Sharp SC, Andershock CJ, Craig SB. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. *Am J Clin Pathol* 1993; **99**: 726-728 [PMID: 8322708]

11 **Berthiot G**, Marechal F, Cattan A, Deltour G. Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung. *Biomed Pharmacother* 1989; **43**: 613-620 [PMID: 2631977 DOI: 10.1016/0753-3322(89)90040-1]

12 **Molina R**, Ojeda B, Filella X, Borras G, Jo J, Mas E, Lopez JJ, Ballesta A. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. *Tumour Biol* 1992; **13**: 278-286 [PMID: 1290025 DOI: 10.1159/000217776]

13 **DelMaschio A**, Vanzulli A, Sironi S, Castrucci M, Mellone R, Staudacher C, Carlucci M, Zerbi A, Parolini D, Faravelli A. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. *Radiology* 1991; **178**: 95-99 [PMID: 1984331 DOI: http: //dx.doi.org/10.1148/radiology.178.1.1984331]

14 **Tempero MA**, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. *Cancer Res* 1987; **47**: 5501-5503 [PMID: 3308077]

15 **Singh S**, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. *Dig Dis Sci* 2011; **56**: 2491-2496 [PMID: 21516323 DOI: 10.1007/s10620-011-1709-8]

16 **Melo SA**, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* 2015; **523**: 177-182 [PMID: 26106858 DOI: 10.1038/nature14581]

17 **Hahn SA**, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996; **271**: 350-353 [PMID: 8553070 DOI: 10.1126/science.271.5247.350]

18 **Hansel DE**, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. *Annu Rev Genomics Hum Genet* 2003; **4**: 237-256 [PMID: 14527303 DOI: 10.1146/annurev.genom.4.070802.110341]

19 **Malkoski SP**, Wang XJ. Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. *FEBS Lett* 2012; **586**: 1984-1992 [PMID: 22321641 DOI: 10.1016/j.febslet.2012.01.054]

20 **Wilentz RE**, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. *Cancer Res* 2000; **60**: 2002-2006 [PMID: 10766191]

21 **Iacobuzio-Donahue CA**, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *J Clin Oncol* 2009; **27**: 1806-1813 [PMID: 19273710 DOI: 10.1200/JCO.2008.17.7188]

22 **Blackford A**, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. *Clin Cancer Res* 2009; **15**: 4674-4679 [PMID: 19584151 DOI: 10.1158/1078-0432.CCR-09-0227]

23 **Tascilar M**, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2001; **7**: 4115-4121 [PMID: 11751510]

24 **Biankin AV**, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. *J Clin Oncol* 2002; **20**: 4531-4542 [PMID: 12454109 DOI: 10.1200/JCO.2002.12.063]

25 **Isaksson-Mettävainio M**, Palmqvist R, Dahlin AM, Van Guelpen B, Rutegård J, Oberg A, Henriksson ML. High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis. *Int J Cancer* 2012; **131**: 779-788 [PMID: 21964812 DOI: 10.1002/ijc.26473]

26 **MacGrogan D**, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. *Oncogene* 1997; **15**: 1111-1114 [PMID: 9285566]

27 **Kang YK**, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. *Hum Pathol* 2002; **33**: 877-883 [PMID: 12378511 DOI: 10.1053/hupa.2002.127444]

28 **Curtin N**. PARP inhibitors for anticancer therapy. *Biochem Soc Trans* 2014; **42**: 82-88 [PMID: 24450632 DOI: 10.1042/BST20130187]

29 **Shrivastav M**, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. *Cell Res* 2008; **18**: 134-147 [PMID: 18157161 DOI: 10.1038/cr.2007.111]

30 **Cancer Genome Atlas Research Network**. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011; **474**: 609-615 [PMID: 21720365 DOI: 10.1038/nature10166]

31 **Bartkova J**, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* 2006; **444**: 633-637 [PMID: 17136093 DOI: 10.1038/nature05268]

32 **Halazonetis TD**, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. *Science* 2008; **319**: 1352-1355 [PMID: 18323444 DOI: 10.1126/science.1140735]

33 **Hall WA**, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. *Oncogene* 2014; **33**: 5450-5456 [PMID: 24276239 DOI: 10.1038/onc.2013.488]

34 **Forbes S**, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR. COSMIC 2005. *Br J Cancer* 2006; **94**: 318-322 [PMID: 16421597 DOI: 10.1038/sj.bjc.6602928]

35 **Zhao R**, Meng F, Wang N, Ma W, Yan Q. Silencing of CHD5 gene by promoter methylation in leukemia. *PLoS One* 2014; **9**: e85172 [PMID: 24454811 DOI: 10.1371/journal.pone.0085172]

36 **Paul S**, Kuo A, Schalch T, Vogel H, Joshua-Tor L, McCombie WR, Gozani O, Hammell M, Mills AA. Chd5 requires PHD-mediated histone 3 binding for tumor suppression. *Cell Rep* 2013; **3**: 92-102 [PMID: 23318260 DOI: 10.1016/j.celrep.2012.12.009]

37 **Koyama H**, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, London WB, Brodeur GM. Mechanisms of CHD5 Inactivation in neuroblastomas. *Clin Cancer Res* 2012; **18**: 1588-1597 [PMID: 22294723 DOI: 10.1158/1078-0432.CCR-11-2644]

38 **Mokarram P**, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H. Distinct high-profile methylated genes in colorectal cancer. *PLoS One* 2009; **4**: e7012 [PMID: 19750230 DOI: 10.1371/journal.pone.0007012]

39 **Mulero-Navarro S**, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. *Epigenetics* 2008; **3**: 210-215 [PMID: 18698156 DOI: 10.4161/epi.3.4.6610]

40 **Wang X**, Lau KK, So LK, Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. *J Biomed Sci* 2009; **16**: 95 [PMID: 19840376 DOI: 10.1186/1423-0127-16-95]

41 **Zhao R**, Yan Q, Lv J, Huang H, Zheng W, Zhang B, Ma W. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. *Lung Cancer* 2012; **76**: 324-331 [PMID: 22186629 DOI: 10.1016/j.lungcan.2011.11.019]

42 **Agrawal N**, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 2011; **333**: 1154-1157 [PMID: 21798897 DOI: 10.1126/science.1206923]

43 **Berger MF**, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. The genomic complexity of primary human prostate cancer.*Nature* 2011; **470**: 214-220 [PMID: 21307934 DOI: 10.1038/nature09744]

44 **Gorringe KL**, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, Campbell IG. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. *Neoplasia* 2008; **10**: 1253-1258 [PMID: 18953434 DOI: 10.1593/neo.08718]

45 **Jones S**, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* 2010; **330**: 228-231 [PMID: 20826764 DOI: 10.1126/science.1196333]

46 **Lang J**, Tobias ES, Mackie R. Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. *Br J Dermatol* 2011; **164**: 1010-1016 [PMID: 21250965 DOI: 10.1111/j.1365-2133.2011.10223.x]

47 **Li M**, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Zhou S, Vogelstein B, Hruban RH, Papadopoulos N, Cai J, Torbenson MS, Kinzler KW. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. *Nat Genet* 2011; **43**: 828-829 [PMID: 21822264 DOI: 10.1038/ng.903]

48 **Okawa ER**, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, Xhao H, Mosse YP, White PS, Brodeur GM. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. *Oncogene* 2008; **27**: 803-810 [PMID: 17667943 DOI: 10.1038/sj.onc.1210675]

49 **Sjöblom T**, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. *Science* 2006; **314**: 268-274 [PMID: 16959974 DOI: 10.1126/science.1133427]

50 **Bagchi A**, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA. CHD5 is a tumor suppressor at human 1p36. *Cell* 2007; **128**: 459-475 [PMID: 17289567 DOI: 10.1016/j.cell.2006.11.052]

51 **Matsuoka S**, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 2007; **316**: 1160-1166 [PMID: 17525332 DOI: 10.1126/science.1140321]

52 **Du X**, Wu T, Lu J, Zang L, Song N, Yang T, Zhao H, Wang S. Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma. *Clin Transl Oncol* 2013; **15**: 198-204 [PMID: 22855185 DOI: 10.1007/s12094-012-0903-2]

53 **Garcia I**, Mayol G, Rodríguez E, Suñol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casala C, Galván P, de Torres C, Mora J, Lavarino C. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. *Mol Cancer* 2010; **9**: 277 [PMID: 20950435 DOI: 10.1186/1476-4598-9-277]

54 **Wong RR**, Chan LK, Tsang TP, Lee CW, Cheung TH, Yim SF, Siu NS, Lee SN, Yu MY, Chim SS, Wong YF, Chung TK. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer. *Gynecol Obstet Invest* 2011; **72**: 203-207 [PMID: 21860208 DOI: 10.1159/000323883]

55 **Wu X**, Zhu Z, Li W, Fu X, Su D, Fu L, Zhang Z, Luo A, Sun X, Fu L, Dong JT. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. *Breast Cancer Res* 2012; **14**: R73 [PMID: 22569290 DOI: 10.1186/bcr3182]

56 **Van Nostrand JL**, Brady CA, Jung H, Fuentes DR, Kozak MM, Johnson TM, Lin CY, Lin CJ, Swiderski DL, Vogel H, Bernstein JA, Attié-Bitach T, Chang CP, Wysocka J, Martin DM, Attardi LD. Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature* 2014; **514**: 228-232 [PMID: 25119037 DOI: 10.1038/nature13585]

57 **Kim HG**, Kurth I, Lan F, Meliciani I, Wenzel W, Eom SH, Kang GB, Rosenberger G, Tekin M, Ozata M, Bick DP, Sherins RJ, Walker SL, Shi Y, Gusella JF, Layman LC. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. *Am J Hum Genet* 2008; **83**: 511-519 [PMID: 18834967 DOI: 10.1016/j.ajhg.2008.09.005]

58 **Tahara T**, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, Kondo Y, Toyota M, Issa JP, Estécio MR. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. *Gastroenterology* 2014; **146**: 530-38.e5 [PMID: 24211491 DOI: 10.1053/j.gastro.2013.10.060]

59 **Bajpai R**, Chen DA, Rada-Iglesias A, Zhang J, Xiong Y, Helms J, Chang CP, Zhao Y, Swigut T, Wysocka J. CHD7 cooperates with PBAF to control multipotent neural crest formation. *Nature* 2010; **463**: 958-962 [PMID: 20130577 DOI: 10.1038/nature08733]

60 **Zentner GE**, Hurd EA, Schnetz MP, Handoko L, Wang C, Wang Z, Wei C, Tesar PJ, Hatzoglou M, Martin DM, Scacheri PC. CHD7 functions in the nucleolus as a positive regulator of ribosomal RNA biogenesis. *Hum Mol Genet* 2010; **19**: 3491-3501 [PMID: 20591827 DOI: 10.1093/hmg/ddq265]

61 **Engelen E**, Akinci U, Bryne JC, Hou J, Gontan C, Moen M, Szumska D, Kockx C, van Ijcken W, Dekkers DH, Demmers J, Rijkers EJ, Bhattacharya S, Philipsen S, Pevny LH, Grosveld FG, Rottier RJ, Lenhard B, Poot RA. Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes. *Nat Genet* 2011; **43**: 607-611 [PMID: 21532573 DOI: 10.1038/ng.825]

62 **Batsukh T**, Schulz Y, Wolf S, Rabe TI, Oellerich T, Urlaub H, Schaefer IM, Pauli S. Identification and characterization of FAM124B as a novel component of a CHD7 and CHD8 containing complex. *PLoS One* 2012; **7**: e52640 [PMID: 23285124 DOI: 10.1371/journal.pone.0052640]

63 **Bamford S**, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer* 2004; **91**: 355-358 [PMID: 15188009 DOI: 10.1038/sj.bjc.6601894]

64 **Gao J**, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013; **6**: pl1 [PMID: 23550210 DOI: 10.1126/scisignal.2004088]

65 **Cerami E**, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012; **2**: 401-404 [PMID: 22588877 DOI: 10.1158/2159-8290.CD-12-0095]

66 **Colbert LE**, Petrova AV, Fisher SB, Pantazides BG, Madden MZ, Hardy CW, Warren MD, Pan Y, Nagaraju GP, Liu EA, Saka B, Hall WA, Shelton JW, Gandhi K, Pauly R, Kowalski J, Kooby DA, El-Rayes BF, Staley CA, Adsay NV, Curran WJ, Landry JC, Maithel SK, Yu DS. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. *Cancer Res* 2014; **74**: 2677-2687 [PMID: 24626090 DOI: 10.1158/0008-5472.CAN-13-1996]

67 **Galluzzi L**, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. *Cell Death Differ* 2007; **14**: 1237-1243 [PMID: 17431418 DOI: 10.1038/sj.cdd.4402148]

68 **Vanlangenakker N**, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. *Cell Death Differ* 2012; **19**: 75-86 [PMID: 22075985 DOI: 10.1038/cdd.2011.164]

69 **Tenev T**, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. *Mol Cell* 2011; **43**: 432-448 [PMID: 21737329 DOI: 10.1016/j.molcel.2011.06.006]

70 **Coupienne I**, Fettweis G, Piette J. RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. *Lasers Surg Med* 2011; **43**: 557-564 [PMID: 22057483 DOI: 10.1002/lsm.21088]

71 **Vandenabeele P**, Declercq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. *Sci Signal* 2010; **3**: re4 [PMID: 20354226 DOI: 10.1126/scisignal.3115re4]

72 **Zhao J**, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu ZG. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proc Natl Acad Sci USA* 2012; **109**: 5322-5327 [PMID: 22421439 DOI: 10.1073/pnas.1200012109]

73 **Sun L**, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell* 2012; **148**: 213-227 [PMID: 22265413 DOI: 10.1016/j.cell.2011.11.031]

74 **Colbert LE**, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW, Petrova AV, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA, Adsay NV, Curran WJ, Landry JC, Maithel SK, Yu DS. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. *Cancer* 2013; **119**: 3148-3155 [PMID: 23720157 DOI: 10.1002/cncr.28144]

75 **He L**, Peng K, Liu Y, Xiong J, Zhu FF. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. *Onco Targets Ther* 2013; **6**: 1539-1543 [PMID: 24204164 DOI: 10.2147/OTT.S52805]

**P-Reviewer:** Aktas S, Kleeff J, Li SD, Pezzilli R **S-Editor:** Qiu S **L-Editor: E-Editor:**

**Table 1 Summary of chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7 and mixed lineage kinase domain-like protein biomarkers in pancreatic adenocarcinoma**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Biomarker** | **Pathway affected** | **Biomarker type for pancreatic cancer from literature and studies? (prognostic, predictive, diagnostic)** | **Mechanism of action** | **Other cancers** | **Comments** |
| CHD5[33] | DDR | Prognostic | Tumor suppressor gene. Binds to histone 3 | Epigenetically silenced in neuroblastoma[37], colorectal cancer[38], breast cancer[39], cervical cancer[39], hepatocarcinoma[39], gastric cancer[40] and lung cancer[41]. Mutations found in head and neck squamous cell carcinoma[42], prostate cancer[43], ovarian cancer[44], ovarian clear cell carcinoma[45], cutaneous melanoma[46], hepatocellular carcinoma[47], neuroblastoma[48], breast and colorectal cancer[49] | Low expression correlates with worse clinical outcomes. |
| CHD7[66] | DDR | Prognostic | Interacts with SOX2 to regulate gene expression | - | Decreased expression is associated with improved clinical outcomes |
| MLKL[74] | Necroptosis | Prognostic | Forms necrosis- inducing complex called a “necrosome” along with RIPK1 and RIPK3 | Ovarian[75] | Low expression is associated with worse clinical outcomes |

DDR: DNA damage response pathway; SOX2: (Sex Determining Region Y)-Box 2; RIPK1: Receptor-interacting serine/threonine-protein kinase 1; RIPK3: Receptor-interacting serine/threonine-protein kinase 1.